CANCvsETF 2ETF Comparison
VS
Choose a second ETF to run a side-by-side ETF comparison with CANC, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
CANC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 07/27/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CANC ETF 2 | -0.28%– | +8.61%– | +18.41%– | +53.77%– | n/a– | n/a– |
| Flows | CANC ETF 2 | -$2M– | +$3M– | +$52M– | +$76M– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CANC ETF 2 | +23.01%– | +22.71%– | n/a– | n/a– |
| Max drawdown | CANC ETF 2 | -5.93%– | -9.20%– | n/a– | n/a– |
| Max drawdown duration | CANC ETF 2 | 47d– | 67d– | n/a– | n/a– |
Trading data
CANC | ETF 2 | |
Last sale 7/28/2026 at 1:30 PM | $41.18 | – |
| Previous close 07/27/2026 | $41.10 | – |
| Consolidated volume 07/27/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Advertisement
Main metrics
Last update 7/28/2026 at 1:30 PM
Live
Closed
CANC | ETF 2 | |
|---|---|---|
| Last price | $41.18 | – |
| 1D performance | +0.20% | – |
| AuM | $195.62 M | – |
| E/R | 0.99% | – |
Characteristics
CANC | ETF 2 | |
|---|---|---|
| Management strategy | Active | – |
| Provider | Tema | – |
| Benchmark | - | – |
| N° of holdings | 56 | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 15, 2023 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
CANC
USA
80.59%
Switzerland
9.85%
Other
9.56%
ETF 2
Sectors
CANC
Healthcare
99.28%
Other
0.72%
ETF 2
Advertisement
Diversification
CANC
Total weight of top 15 holdings out of 15
55.76%
ETF 2
–
Top 15 holdings
Data as of June 30, 2026
CANC
Revolution Medicines, Inc.
6.32%
Eli Lilly & Co.
5.24%
Cogent Biosciences, Inc.
4.94%
Novartis AG
4.19%
Roche Holding AG
3.93%
Legend Biotech Corp.
3.70%
Merck & Co., Inc.
3.66%
Bristol Myers Squibb Co.
3.33%
AstraZeneca PLC
3.15%
Johnson & Johnson
3.09%
AbbVie, Inc.
3.08%
Immunome, Inc.
2.87%
Exelixis, Inc.
2.85%
Nuvalent, Inc.
2.73%
IDEAYA Biosciences, Inc.
2.68%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
